0001209191-21-070565.txt : 20211220 0001209191-21-070565.hdr.sgml : 20211220 20211220162249 ACCESSION NUMBER: 0001209191-21-070565 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211216 FILED AS OF DATE: 20211220 DATE AS OF CHANGE: 20211220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goeltz II Robert C. CENTRAL INDEX KEY: 0001653881 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38419 FILM NUMBER: 211505547 MAIL ADDRESS: STREET 1: 343 OYSTER POINT BLVD STREET 2: SUITE 100 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcus Biosciences, Inc. CENTRAL INDEX KEY: 0001724521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473898435 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (510) 694-6200 MAIL ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-16 0 0001724521 Arcus Biosciences, Inc. RCUS 0001653881 Goeltz II Robert C. C/O ARCUS BIOSCIENCES, INC. 3928 POINT EDEN WAY HAYWARD CA 94545 0 1 0 0 Chief Financial Officer Common Stock 2021-12-16 4 S 0 354 39.5916 D 7771 D Common Stock 2021-12-16 4 S 0 131 40.4565 D 7640 D Common Stock 2021-12-17 4 S 0 138 38.7877 D 7502 D Common Stock 2021-12-17 4 S 0 88 39.6719 D 7414 D Common Stock 2021-12-17 4 S 0 171 40.5732 D 7243 D Common Stock 2021-12-17 4 S 0 224 41.4238 D 7019 D Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.11 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $40.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.10 to $41.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Carolyn Tang, Attorney-in-Fact 2021-12-20